Physician profile
Gregg Koval
NPI 1659472363
$4,305.26
in general payments reported to CMS, 2019-2025
41 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $116 · 2021: $17.47 · 2022: $336 · 2023: $1,044 · 2024: $1,147 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127 · Entertainment: $13.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.27 |
| Entertainment | $13.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $569.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $537.44 | 2019-2025 | |
| Abbvie INC. | $452.19 | 2019-2025 | |
| Amgen INC. | $347.94 | 2019-2025 | Prolia, Evenity, Krystexxa |
| Novartis Pharmaceuticals Corporation | $300.28 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $265.51 | 2019-2025 | |
| Lilly USA, LLC | $217.38 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $144.96 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $142.40 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $123.70 | 2023-2025 | |
| Atricure, INC. | $107.83 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $104.30 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $97.37 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $90.31 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $82.53 | 2023-2025 | Cologuard Collection Kit |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $69.71 | 2023-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $67.96 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.92 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Phathom Pharmaceuticals, INC. | $42.48 | 2024 | Voquezna |
| Dexcom, INC. | $34.65 | 2023-2024 | Dexcom G6 Transmitter |
| Sandoz INC. | $33.05 | 2025 | |
| Sanofi Pasteur INC. | $30.65 | 2022 | |
| Boston Scientific Corporation | $30.15 | 2025 | Bodyguardian |
| Recordati_rare_diseases_inc. | $28.86 | 2025 | Isturisa |
| Eisai INC. | $28.37 | 2025 | |
| Inspire Medical Systems, INC. | $24.39 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $23.05 | 2024 | Opsumit, Uptravi |
| Madrigal Pharmaceuticals | $22.16 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $21.85 | 2025 | Strensiq |
| Daiichi Sankyo INC. | $21.55 | 2022 | |
| Duchesnay USA Incorporated | $20.30 | 2019 | |
| Neurocrine Biosciences, INC. | $20.02 | 2025 | |
| Ascendis Pharma Endocrinology INC | $18.69 | 2024 | |
| Ibsa Pharma INC. | $18.52 | 2025 | Tirosint, Licart, Flector |
| Merck Sharp & Dohme LLC | $18.51 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Amneal Pharmaceuticals LLC | $18.44 | 2025 | Unithroid |
| Amarin Pharma, INC. | $17.66 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.02 | 2019 | |
| Currax Pharmaceuticals LLC | $14.10 | 2019 | |
| Optos, INC. | $13.47 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Koval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.